ARTEMIS

a Randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national cardiovascular outcome trial to evaluate the effect of ziltivekimab 15mg versus placebo, both added to standard of care, on CV outcomes in participants with AMI (NSTEMI/STEMI) and angiographic evidence of type 1 MI.